Italia markets open in 6 hours 55 minutes

United Therapeutics Corporation (UTHR)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
207,94-3,14 (-1,49%)
Alla chiusura: 04:00PM EDT
207,94 0,00 (0,00%)
Dopo ore: 04:04PM EDT

United Therapeutics Corporation

1040 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
https://www.unither.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno965

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.Founder, Chairman & CEO3,51M5,08M1955
Mr. Michael I. BenkowitzPres & COO1,96M17,34M1972
Mr. James C. EdgemondCFO & Treasurer1,42MN/D1968
Mr. Paul A. Mahon J.D.Exec. VP, Gen. Counsel & Corp. Sec.1,67M12,39M1964
Mr. Dewey Steadman C.F.A.Head of Investor RelationsN/DN/DN/D
Ms. Holly HobsonAssociate VP of HRN/DN/DN/D
Kevin T. GraySr. VP of Strategic Operations & LogisticsN/DN/DN/D
Mr. Patrick PoissonExec. VP of Technical OperationsN/DN/D1968
Mr. Gil GoldenSr. VP & Chief Medical OfficerN/DN/DN/D
Dr. Leigh PetersonVP of Product Devel.N/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Governance aziendale

L'ISS Governance QualityScore di United Therapeutics Corporation al 1 settembre 2022 è 2. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.